Patents Assigned to Symbicom AB
-
Patent number: 6090586Abstract: The present invention relates to nucleic acid molecules, polypeptides encoded by the same, antibodies directed thereto and a method of preparing such polypeptides including: (a) inserting an isolated DNA molecule coding for a polypeptide which is immunoreactive with a 66 kDa polypeptide derived from Borrelia garinii IP90 into an expression vector; (b) transforming a host organism or cell with the vector; (c) culturing the transformed host cell under suitable conditions; and (d) harvesting the polypeptide. The isolated DNA molecule is preferably at least 10 nucleotides in length, and the method may optionally include subjecting the polypeptide to post-translational modification. The host cell can be a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.Type: GrantFiled: June 6, 1995Date of Patent: July 18, 2000Assignee: Symbicom ABInventors: Sven Bergstrom, Alan George Barbour
-
Patent number: 6083722Abstract: Disclosed and claimed are Lyme disease vaccines and methods for making and using them. The vaccines include a vector containing DNA encoding OspA or an immunogenic fragment thereof or such DNA encoding OspA or an immunogenic fragment thereof which has been modified by substitution, addition, insertion or deletion of one or more nucleotides, whereby the DNA when expressed results in OspA, or an immunogenic fragment thereof, or a polypeptide having the immunological activity of OspA or the fragment thereof.Type: GrantFiled: June 6, 1995Date of Patent: July 4, 2000Assignee: Symbicom ABInventors: Sven Bergstrom, Alan G. Barbour, Louis A. Magnarelli
-
Patent number: 6068842Abstract: The present invention relates to nucleic acid molecules, polypeptides encoded by the same, antibodies directed thereto and a method of preparing such polypeptides including: (a) inserting an isolated DNA molecule coding for a polypeptide which is immunoreactive with a 66 kDa polypeptide derived from Borrelia garinii IP90 into an expression vector; (b) transforming a host organism or cell with the vector; (c) culturing the transformed host cell under suitable conditions; and (d) harvesting the polypeptide. The isolated DNA molecule is preferably at least 10 nucleotides in length, and the method may optionally include subjecting the polypeptide to post-translational modification. The host cell can be a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.Type: GrantFiled: June 6, 1995Date of Patent: May 30, 2000Assignee: Symbicom ABInventors: Sven Bergstrom, Alan George Barbour
-
Patent number: 6054296Abstract: The present invention relates to nucleic acid molecules, polypeptides encoded by the same, antibodies directed thereto and a method of preparing such polypeptides including: (a) inserting an isolated DNA molecule coding for a polypeptide which is immunoreactive with a 66 kDa polypeptide derived from Borrelia garinii IP90 into an expression vector; (b) transforming a host organism or cell with the vector; (c) culturing the transformed host cell under suitable conditions; and (d) harvesting the polypeptide. The isolated DNA molecule is preferably at least 10 nucleotides in length, and the method may optionally include subjecting the polypeptide to post-translational modification. The host cell can be a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.Type: GrantFiled: June 20, 1994Date of Patent: April 25, 2000Assignee: Symbicom ABInventors: Sven Bergstrom, Alan George Barbour
-
Patent number: 4859769Abstract: A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.Type: GrantFiled: November 5, 1986Date of Patent: August 22, 1989Assignee: Symbicom ABInventors: Karl-Anders Karlsson, Erling Norrby, Goran Wadell